Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma

Translational Pediatrics
Hamid BassiriMichael D Hogarty

Abstract

Neuroblastoma is a childhood tumor in which MYC oncogenes are commonly activated to drive tumor progression. Survival for children with high-risk neuroblastoma remains poor despite treatment that incorporates high-dose chemotherapy, stem cell support, surgery, radiation therapy and immunotherapy. More effective and less toxic treatments are sought and one approach under clinical development involves re-purposing the anti-protozoan drug difluoromethylornithine (DFMO; Eflornithine) as a neuroblastoma therapeutic. DFMO is an irreversible inhibitor of ornithine decarboxylase (Odc), a MYC target gene, bona fide oncogene, and the rate-limiting enzyme in polyamine synthesis. DFMO is approved for the treatment of Trypanosoma brucei gambiense encephalitis ("African sleeping sickness") since polyamines are essential for the proliferation of these protozoa. However, polyamines are also critical for mammalian cell proliferation and the finding that MYC coordinately regulates all aspects of polyamine metabolism suggests polyamines may be required to support cancer promotion by MYC. Pre-emptive blockade of polyamine synthesis is sufficient to block tumor initiation in an otherwise fully penetrant transgenic mouse model of neuroblastoma drive...Continue Reading

Citations

Nov 9, 2018·The Journal of Biological Chemistry·André S Bachmann, Dirk Geerts
Oct 26, 2018·The Journal of Biological Chemistry·Eugene W GernerAlfred Cohen
Jan 11, 2020·Cancer Metastasis Reviews·Hisham F BahmadWassim Abou-Kheir
Sep 30, 2016·The Biochemical Journal·Tracy R Murray-StewartRobert A Casero
Jun 23, 2019·Cellular and Molecular Life Sciences : CMLS·Francisca Sánchez-JiménezJosé Luis Urdiales
Apr 25, 2019·Amino Acids·Yvonne L LatourKeith T Wilson
Aug 30, 2018·Children·Valeria Smith, Jennifer Foster
Jan 29, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alice L YuPaul M Sondel
Jun 16, 2021·Cancer Chemotherapy and Pharmacology·Chad R SchultzAndré S Bachmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

African Trypanosomiasis

African trypanosomiasis, also known as sleeping sickness, is an insect-borne parasitic disease of humans and other animals. It is caused by protozoa of the species Trypanosoma brucei and almost invariably progresses to death unless treated. Discover the latest research on African trypanosomiasis here.

© 2021 Meta ULC. All rights reserved